A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with extensive-stage small cell lung cancer.

Trial Details

NCT ID
NCT05924841
Phase
PHASE2
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BL-B01D1
  • SI-B003
Locations (sample)
  • Changchun, Jilin, China|43.88,125.32278

Key Eligibility Criteria

  • All subjects voluntarily participated in the study and signed informed consent;
  • Male or female aged ≥18 years and ≤75 years;
  • Expected survival time ≥3 months;
  • Patients with extensive-stage small-cell Lung cancer confirmed by histopathology and/or cytology (according to Veterans Administration Lung Study G…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →